Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Laboratory Medicine

Official Journal of the German Society of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Schuff-Werner, Peter

Ed. by Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Bietenbeck, Andreas / Conrad, Karsten / Findeisen, Peter / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / Meyer, Alexander von / Nebe, Carl Thomas / Orth, Matthias / Röhrig-Herzog, Gabriele / Sack, Ulrich / Steimer, Werner / Weber, Thomas / Wieland, Eberhard / Winter, Christof / Zettl, Uwe K.

IMPACT FACTOR 2018: 0.389

CiteScore 2018: 0.22

SCImago Journal Rank (SJR) 2018: 0.156
Source Normalized Impact per Paper (SNIP) 2018: 0.089

See all formats and pricing
More options …
Volume 39, Issue 4


Role of ischemia-modified albumin in clinical practice

Ali Kemal Erenler / Türker Yardan / Celal Kati / Mehmet Altuntaş / Süleyman Türedi
Published Online: 2015-06-22 | DOI: https://doi.org/10.1515/labmed-2015-0038


Difficulty in establishing a diagnosis of acute coronary syndrome (ACS) in the clinical setting has led researchers to investigate novel markers that show increased blood levels before the myocardial necrosis occurs. In ischemic conditions, some modifications occur in the amino acids located on the N-terminus of the human albumin molecule. Ischemia-modified albumin (IMA) is a marker formed after damage in the N-terminal region of albumin. The altered N-terminus can no longer bind transition metals, such as cobalt. The causes of the increases in IMA have been shown to be endothelial or extracellular hypoxia, acidosis, and free oxygen radicals. IMA, an early marker of ischemic disorders, is also a candidate marker for the detection of ACS. An assay measuring IMA might represent a promising marker for the identification of patients with myocardial ischemia. The aim of this study was to evaluate the clinical utility of IMA in the assessment of ACS as well as other medical disorders in light of the recent literature.

Reviewed publication


Keywords: acute coronary syndrome; biochemistry; ischemia-modified albumin


  • 1.

    Roberts RR, Zalenski RJ, Mensah EK, Rydman RJ, Ciavarella G, Gussow L, et al. Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain: a randomized controlled trial. J Am Med Assoc 1999;278:1670–6.CrossrefGoogle Scholar

  • 2.

    Green GB, Hill PM. Chest pain cardiac or not. In: Tintinalli JE, editor. Tintinalli’s emergency medicine. A comprehensive study guide, 7th ed. New York (NY): McGraw-Hill, 2011:361–7.Google Scholar

  • 3.

    Aggarwal K, Seth S, Dahiya K, Aggarwal HK, Aggarwal MK. Ischemia modified albumin in patients of cardiac and non-cardiac chest pain. Biomed Res 2011;23:61–5.Google Scholar

  • 4.

    Anwaruddin S, Januzzi JL, Baggish AL, Lewandrowsky EL, Lewandrowsky KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140–5.CrossrefPubMedGoogle Scholar

  • 5.

    Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810–24.PubMedCrossrefGoogle Scholar

  • 6.

    Aslan D, Apple FS. Ischemia modified albumin measured by the albumin cobalt binding test: a clinical and analytical review. Lab Med 2004;35:44–7.CrossrefGoogle Scholar

  • 7.

    He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992;358:209–15.CrossrefPubMedGoogle Scholar

  • 8.

    Predki PF, Harford C, Brar P, Sarkar B. Further characterization of the N-terminal copper (II) and nickel (II) binding motif of proteins. Studies of metal binding to chicken serum albumin and the native sequence peptide. Biochem J 1992;287:211–5.CrossrefGoogle Scholar

  • 9.

    Bali L, Cuisset T, Giorgi R, Monserrat C, Quilici J, Carrega L, et al. Prognostic value of ischaemia-modified albumin in patients with non-ST-segment elevation acute coronary syndromes. Arch Cardiovasc Dis 2008;101:645–51.PubMedCrossrefGoogle Scholar

  • 10.

    Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42–7.Google Scholar

  • 11.

    Erturk E, Cekic B, Geze S, Kosucu M, Coskun I, Eroglu A, et al. Comparison of the effect of propofol and N-acetylcysteine in preventing ischaemia-reperfusion injury. Eur J Anaesthesiol 2009;26:279–84.CrossrefGoogle Scholar

  • 12.

    Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers 2010;15:655–62.CrossrefGoogle Scholar

  • 13.

    Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of “ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29–34.PubMedCrossrefGoogle Scholar

  • 14.

    ACBR Test Reagent Pack, COBAS MIRAR Plus. Package insert, August 2002.Google Scholar

  • 15.

    Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 2006;48:2482–4.CrossrefPubMedGoogle Scholar

  • 16.

    Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobaltbinding test after a marathon race. Clin Chem 2002;48:1097–100.PubMedGoogle Scholar

  • 17.

    Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J. Ischemia modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063–5.CrossrefGoogle Scholar

  • 18.

    Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261–2.CrossrefPubMedGoogle Scholar

  • 19.

    Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959–69.Google Scholar

  • 20.

    Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It’s time for a change to a troponin standard. Circulation 2000;102:1216–20.CrossrefGoogle Scholar

  • 21.

    Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or nondiagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004;97:297–301.CrossrefGoogle Scholar

  • 22.

    Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart-type fatty acid binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values. J Clin Lab Anal 2009;23:14–8.PubMedCrossrefGoogle Scholar

  • 23.

    Chawla R, Goyal N, Calton R, Goyal S. Ischemia modified albumin: a novel marker for acute coronary syndrome. Indian J Clin Biochem 2006;21:77–82.PubMedCrossrefGoogle Scholar

  • 24.

    Behera S, Mangaraj M, Mohapatra PC. Diagnostic efficacy of ischemia modified albumin and its correlation with lipid profile, oxidative stress in acute myocardial infarct patients on admission. Asian Pac J Trop Dis 2012;2:62–5.Google Scholar

  • 25.

    Bhardwaj A, Truong QA, Peacock WF, Yeo KT, Storrow A, Thomas S. A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department. Am Heart J 2011;162:276–82.CrossrefPubMedGoogle Scholar

  • 26.

    Charpentier S, Ducasse JL, Cournot M, Maupas-Schwalm F, Elbaz M, Baixas C, et al. Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of nonST-elevation acute coronary syndrome in the emergency department. Acad Emerg Med 2010;17:27–35.CrossrefGoogle Scholar

  • 27.

    Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G. OPERA Investigators. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 2010;159:570–6.PubMedCrossrefGoogle Scholar

  • 28.

    Maneewong K, Mekrungruangwong T, Luangaram S, Thongsri T, Kumphune S. Combinatorial determination of ischemia modified albumin and protein carbonyl in the diagnosis of non ST elevation myocardial infarction. Indian J Clin Biochem 2011;26:389–95.CrossrefPubMedGoogle Scholar

  • 29.

    Ozdem S, Cete Y, Donmez L, Basarici I, Baktir A, Akbas H, et al. Serum levels of ischemia-modified albumin (IMA) in healthy adults and patients with acute coronary syndrome. Tr J Emerg Med 2005;5:169–74.Google Scholar

  • 30.

    Talwalkar SS, Bon Homme M, Miller JJ, Elin RJ. Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci 2008;38:132–7.Google Scholar

  • 31.

    Koc ZP, Erkilic M, Basarici I, Deger N, Ozdem S, Saka O. Ischemia modified albumin levels cannot predict stress induced ischemia shown by myocardial perfusion scintigraphy. Rev Esp Med Nucl Imagen Mol 2012;31:202–6.PubMedGoogle Scholar

  • 32.

    Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253–62.PubMedCrossrefGoogle Scholar

  • 33.

    Toker A, Aribas A, Yerlikaya FH, Tasyurek E, Akbuğa K. Serum and saliva levels of ischemia-modified albumin in patients with acute myocardial infarction. J Clin Lab Anal 2013;27:99–104.PubMedCrossrefGoogle Scholar

  • 34.

    Mentese A, Mentese U, Turedi S, Gunduz A, Karahan SC, Topbas M. Effect of deep vein thrombosis on ischaemia-modified albumin levels. Emerg Med J 2008;25:811–4.PubMedCrossrefGoogle Scholar

  • 35.

    Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, et al. The value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007;25:770–3.CrossrefPubMedGoogle Scholar

  • 36.

    Turedi S, Gunduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res 2008;9:49.CrossrefPubMedGoogle Scholar

  • 37.

    Turedi S, Cinar O, Kaldirim U, Mentese A, Tatli O, Cevik E, et al. Ischemia-modified albumin levels in carbon monoxide poisoning. Am J Emerg Med 2011;29:675–81.PubMedCrossrefGoogle Scholar

  • 38.

    Gunduz A, Turkmen S, Turedi S, Mentese A, Yulug E, Ulusoy H, et al. Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 2009;16:539–43.CrossrefPubMedGoogle Scholar

  • 39.

    Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, et al. Ischemiamodified albumin in acute stroke. Cerebrovasc Dis 2007;23:216–20.PubMedCrossrefGoogle Scholar

  • 40.

    Gunduz A, Turedi S, Mentese A, Altunayoglu V, Turan I, Karahan SC, et al. Ischemiamodified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008;26:874–8.CrossrefPubMedGoogle Scholar

  • 41.

    Cichota LC, Moresco RN, Duarte MM, da Silva JE. Evaluation of ischemia-modified albumin in anaemia associated to chronic kidney disease. J Clin Lab Anal 2008;22:1–5.CrossrefPubMedGoogle Scholar

  • 42.

    Turedi S, Cinar O, Yavuz I, Mentese A, Gunduz A, Karahan SC, et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 2010;23:335–40.PubMedGoogle Scholar

  • 43.

    Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Ischemiamodified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493–502.PubMedCrossrefGoogle Scholar

  • 44.

    Troxler M, Thompson D, Homer-Vanniasinkam S. Ischaemic skeletal muscle increases serum ischaemia modified albumin. Eur J Vasc Endovasc Surg 2006;31:164–9.CrossrefPubMedGoogle Scholar

  • 45.

    Lippi G, Brocco G, Salvagno GL, Montagnana M, Dima F, Guidi GC. High-workload endurance training may increase serum ischemia-modified albumin concentrations. Clin Chem Lab Med 2005;43:741–4.CrossrefPubMedGoogle Scholar

  • 46.

    Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004;50:1656–60.PubMedCrossrefGoogle Scholar

  • 47.

    Mentese A, Koksal I, Sumer AU, Arslan M, Karahan SC, Yılmaz G. Diagnostic and prognostic value of ischemia-modified albumin in patients with Crimean-Congo hemorrhagic fever. J Med Virol 2013;85:684–8.CrossrefPubMedGoogle Scholar

  • 48.

    Zuwała-Jagiełło J, Warwas M, Pazgan-Simon M. Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation. Acta Biochim Pol 2012;59:661–7.Google Scholar

  • 49.

    Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus – preliminary report. Dis Markers 2008;24:311–7.PubMedGoogle Scholar

  • 50.

    Toker A, Mehmetoglu I, Yerlikaya FH, Nergiz S, Kurban S, Gok H. Investigation of oxidative stress markers in essential hypertension. Clin Lab 2013;59:107–14.PubMedGoogle Scholar

  • 51.

    Mehmetoğlu I, Kurban S, Yerlikaya FH, Polat H. Obesity is an independent determinant of ischemia-modified albumin. Obes Facts 2012;5:700–9.PubMedCrossrefGoogle Scholar

  • 52.

    Uzel M, Oray NC, Bayram B, Kume T, Girgin MC, Doylan O, et al. Novel biochemical marker for differential diagnosis of seizure: ischemia-modified albumin. Am J Emerg Med 2014;32: 962–5.PubMedCrossrefGoogle Scholar

  • 53.

    Dahiya K, Kulshrestha MR, Bansal P, Ghalaut VS, Kulshrestha R, Dahiya P, et al. Evaluation of cord blood ischemia modified albumin in normal pregnancies and preeclampsia. Hypertens Pregnancy 2015;34:204–8.PubMedCrossrefGoogle Scholar

  • 54.

    Ereren E, Erenler AK, Karavelioğlu Y, Kocabaş R, Erdemli HK. Ischemia-modified albumin is not elevated in deep venous thrombosis. Clin Lab 2015;61:513–6.PubMedGoogle Scholar

  • 55.

    Ellidag HY, Eren E, Aydin O, Akgol E, Yalcinkaya S, Sezer C, et al. Ischemia modified albumin levels and oxidative stress in patients with bladder cancer. Asian Pac J Cancer Prev 2013;14:2759–63.Google Scholar

  • 56.

    Ellidag HY, Bulbuller N, Eren E, Abusoglu S, Akgol E, Cetiner M, et al. Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma? Gut Liver 2013;7:675–80.CrossrefPubMedGoogle Scholar

  • 57.

    Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB, et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin Lab 2014;60:1703–8.Google Scholar

About the article

Correspondence: Ali Kemal Erenler, MD, Hitit University, Çorum Education and Research Hospital, Çorum, Turkey, Tel.: +90 364 223 0300, E-Mail:

Received: 2015-03-23

Accepted: 2015-05-29

Published Online: 2015-06-22

Published in Print: 2015-07-01

Citation Information: LaboratoriumsMedizin, Volume 39, Issue 4, Pages 241–247, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/labmed-2015-0038.

Export Citation

©2015 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Comments (0)

Please log in or register to comment.
Log in